Group items tagged

Market Overview: Skin substitutes are natural, synthetic or biosynthetic materials, used to cover large wounds to restore at least some of the functions of the skin. Skin substitutes provides temporary or permanent wound closure and protect the wound from infection, further damage and water loss, and reduce pain. They also facilitate the growth of the normal skin over the wound. Skin substitutes provide a permanent solution and are used in the treatment of conditions like burns, trauma wounds, diabetes or venous ulcers, where skin grafts may not be possible. Market Dynamics: Rising chronic skin diseases is expected to drive the skin substitutes market. For instance, according to the global burden of disease study 2013, Skin conditions contributed around 1.79% to the global disease burden. According to the World Health Organization, about 132,000 melanoma skin cancers occur each year worldwide. Thus, the rising chronic diseases is increasing the demand for skin substitutes in the forecast period. Rising prevalence of diabetes is expected to boost the market. This is owing to the risk of developing a diabetic foot ulcer over the period of time in diabetic patients. For instance, WHO has reported that the incidence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is anticipated to rise from 171 million in 2000 to 366 million in 2030. Thus, as a consequence, the prevalence of diabetes related complications are expected to increase over the forecast period. There are several limitations to the commercially available skin substitutes, like reduced vascularization, poor mechanical integrity, failure to integrate, scarring, and immune rejection. Market Segmentation: Rise in preference for acellular skin substitutes to implant-based skin surgery is expected to drive the growth of the skin substitutes market. For instance, the American Society of Plastic Surgeons in 2012, reported that

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o

Companion animals are domesticated or domestic-bred animals whose physical, emotional, behavioral and social needs can be readily met as companions in the home or a close daily relationship with humans. Companion animal health market mainly comprises of medicines, medicinal feed additives, and vaccines and caters to both foods producing and companion animals. China Companion Animal Health Market was worth US$ XX Million in 2019 and is expected to reach US$ XX Million by 2026, at a CAGR of XX% during the forecast period 2019-2026. Download Free Sample Report: https://www.datamintelligence.com/download-sample/china-companion-animal-health-market View Full Report Sample: https://www.datamintelligence.com/research-report/china-companion-animal-health-market

Chronic Immune Thrombocytopenia (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes, causing a decrease in platelet production. The global chronic immune thrombocytopenia market size was worth $ XX billion in 2019 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period (2019-2026). View Full Report Sample: https://www.datamintelligence.com/research-report/chronic-immune-thrombocytopenia-market Download free Report Sample: https://www.datamintelligence.com/download-sample/chronic-immune-thrombocytopenia-market

The global biopharmaceuticals market is set to exhibit a CAGR of 7.83% during 2019-2026 and is estimated to reach a market value of US $ XX billion by 2026. Biopharmaceuticals are large and complex molecular drugs that are mainly obtained from proteins and nucleic acids of living organisms such as microorganisms and animal cells also known as transgenic organisms. These drugs are obtained using biotechnology and have high-therapeutic value. Biopharmaceuticals are also known as biologics and biotech drugs and are usually administered by intravenous, subcutaneous, or intramuscular injections and are more efficient than the conventional small molecule drugs. Biopharmaceuticals are an alternative to the previously less effective and sometimes unsafe treatments and offer several benefits. Biopharmaceuticals benefits include highly effective and potent action, fewer side effects, can be tailored according to specific medical requirements of patients and they hold the potential to actually cure diseases at the root level. Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade and have changed the treatment of several chronic diseases, such as diabetes and cardiovascular diseases. Download free Report Sample: https://www.datamintelligence.com/download-sample/biopharmaceuticals-market View Full Report Sample: https://www.datamintelligence.com/research-report/biopharmaceuticals-market

"An increase in brain inflammation, such as that caused by age, diabetes and obesity, is known to increase risk for developing Alzheimer's disease. Now scientists at UK's Southampton University are about to start a three-year study, using brain tissue generously donated by people who died with Alzheimer's disease, to see if inflammation caused by infections such as those of the urinary tract or chest, also speeds up progress of the disease." - medical news today In an announcement released on Wednesday, study leader Delphine Boche, Lecturer in Clinical Neurosciences at Southampton, says: "Many of the known risk factors for Alzheimer's, like age, obesity and diabetes, increase inflammation in the brain and we think that infections could be another risk factor." "There is already evidence that the immune system is on high alert in people with Alzheimer's and we think that an extra trigger, like an infection, could tip the balance and make immune cells switch from being protective to harmful," she adds. Alzheimer's Research UK has already put £300,000 into the project. The money is part of the charity's £20m investment in leading dementia research in the UK. The study started in January 2013, and will add to the growing pile of evidence that shows how the immune system is implicated in Alzheimer's disease. The Southampton team believes that in Alzheimer's, the immune system goes beyond its role as protector of the body and starts causing damage, like it does in an autoimmune disease. For their study, Boche and colleagues will use brain tissue generously donated by people who had Alzheimer's disease when they died. With reference to donors' medical records, the researchers will compare the brains of those who had infections when they died with those who did not. They will be particularly interested in immune cells known as "microglia", which go around mopping up cellular debris. They will use fluorescent tags to label the cells in the brain, and look

Health regulators are including warning to the medicine labels of popular cholesterol-lowering drugs that they might increase blood sugar and possibly cause memory loss. FDA has publicized last week that there has been alterations in the safety information labels of statins of Merck & Co's, AstraZeneca and Pfizer - medicines that are used by millions of Americans. Statins have long proven that it is effective in reducing the risk of heart attack and other heart disorders and, according to FDA, this new development must not scare people into halting the use of the medicines. FDA announced that they know of studies wherein several patients taking statins might have an increased risk of having high sugar levels in the blood and, eventually, of being diagnosed with diabetes. They have apparently known for 4 years now that statin 'slightly' increases blood sugar but they are insisting that this does not change that statins are effective in reducing heart risk for patients. This is the first time that FDA has officially connected the use of statin to cognitive disorders like confusion and forgetfulness, even though several patients have already reported those problems for years. The drugs affected include big brands such as Vytorin, Crestor, Zocor and Lipitor.

"Pursue healthy lifestyle parameters to cut the danger of high blood pressure" - springhill medical One of the most significant risk factors for cardiovascular disease that leads to an estimated 15 percent of all deaths worldwide each year is hypertension or high blood pressure. Micro-cracks in the inner lining of arterial walls are caused by an excessive blood pressure consequently leads to a series of serious health concerns. Patching materials are hurriedly pulled from blood circulation to fix the cracks; this is in a desperate attempt to prevent a potentially deadly hemorrhage. This may save you today and can continue a life for a while but over the course of several decades, plaque volume increases until blood flow is cut off to the heart and brain, or a clot becomes lodged in a narrowed artery. There are a number of important lifestyle factors according to medical researchers. These factors increase the risk for hypertension. They also found out that blood pressure can be returned to normal without the need for pharmaceuticals that are ineffective and wrought with deadly side-effects by modifying these actions. Healthy behaviors regarding alcohol, physical activity, vegetable intake and body weight reduce the risk of hypertension by two-thirds; this is according to the research team from Finland reporting to the European Society of Cardiology Congress. Prevention of hypertension is essential to improving health and preventing morbidity and mortality, they further noted. Smoking, alcohol consumption, physical activity, obesity and consumption of vegetables are the five major cardiovascular disease-related lifestyle factors the have identified... Main article: http://springhillmedgroup.com/

Wow, I am grateful for knowing you! A lesson for us all to dwell in possibility.

Taco Bell was well-known as one of the purveyor of junk food and they wanted to start erasing that from our memory yet they are not ready to give up the chalupa yet. Wednesday, the chain announced that it's exploring ways to offer more "balanced choices," marking just the latest sign that the fast-food industry is trying to adapt to shifting tastes and upend the conventional wisdom that it only offers caloric indulgences. Taco Bell is testing a "range of products" this year, with national launches planned for 2014. He also said existing menu items could also be reformulated but noted that the chain would remain true to its brand, CEO Greg Creed said. "We're not going to walk away from who Taco Bell is," Creed stated. Taco Bell says, by 2020, 20% of its combo meals will meet nutritional guidelines for calories and fat set out by the federal government. People eat three meals a day, as a general thought, that means a single meal would have about a third of the recommended intake of about 2,000 to 2,500 calories. The company has no idea of what portion of meals currently meet those guidelines. Taco Bell is known for urging people to eat nachos as a "fourth meal" late at night, it is a bit of a contrary to the announcement and it gained a lot of skeptics. However it demonstrates just how much difficulty the broader industry is facing to overturn its greasy-food image as people more and more look out for alternatives they believe are healthier. The lower-calorie options were a key indicator of growth at restaurant chains between 2006 and 2011 from a report by the Hudson Institute earlier this year. The increase in customer traffic rise by 11 per cent by those chains that expanded while those that didn't saw traffic fall by 15 per cent, according to the public policy research group. As customer "tastes and needs" evolve, Creed said that offering more balanced choices would be critical in helping Taco Bell reach its growth targets over the next

Thanks for another informative site. Where else could I get that type of information written in such an ideal way? I've a project that I am just now working on, and I have been on the look out for such info.

The Global Diabetic Foot Ulcer Market was valued at $4.48 billion in 2018 and is anticipated to exhibit 11.34% CAGR from 2019 to 2026, reaching $ XX billion by 2026.